-
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients : results of a 1-year follow-up study from the CERERRA collaborationChatzidionysiou, Katerina ...Objectives: To compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide. Methods: 10 European registries submitted anonymised datasets with ... baseline, 3, 6, 9 and 12-month clinical data from patients who started rituximab. Results: 1195 patients weretreated with rituximab plus methotrexate, 177 with rituximab plus leflunomide and 505 with rituximab alone. Significantly more patients achieveda European League Against Rheumatism good response at 6 months when treated with rituximab plus leflunomide (29.1%) compared with rituximab plus methotrexate (21.1%) and rituximab alone (19.3%; p=0.02 and p=0.01, respectively). Similar results were observed at 12 months. Adverse events occurred in 10.2%, 13.2% and 13.9% of patients on rituximab plus leflunomide, rituximab plus methotrexate and rituximab alone, respectively. Conclusions: Leflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab. Slightly better results were obtained bythe combination of rituximab and leflunomide than rituximab and methotrexate, raising the possibility of a synergistic effect of leflunomide and rituximab.Source: Annals of the Rheumatic Diseases. - ISSN 0003-4967 (Vol. 71, iss. 3, 2012, str. 374-377)Type of material - article, component partPublish date - 2012Language - englishCOBISS.SI-ID - 29859801
Author
Chatzidionysiou, Katerina |
Lie, Elisabeth |
Nasonov, Evgen |
Tomšič, Matija, 1959-
Topics
Adult |
Aged |
Antirheumatic Agents |
Adverse Effects |
Therapeutic Use |
Arthritis, Rheumatoid |
Drug Therapy |
Drug Therapy, Combination |
Epidemiologic Methods |
Immunosuppressive Agents |
Adverse Effects |
Therapeutic Use |
Isoxazoles |
Administration & Dosage |
Adverse Effects |
Methotrexate |
Administration & Dosage |
Adverse Effects |
Product Surveillance, Postmarketing |
Methods |
Treatment Outcome |
Artritis revmatični |
Starostniki |
Odrasli |
Produkt, preiskovanje postmarketinško |
Imunosupresivi |
Metotreksat |
Zdravljenje, izid |
Antirevmatiki |
Zdravilo, terapija sestavljena |
Epidemiološke metode |
Izoksazoli
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
| Year | Impact factor | Edition | Category | Classification | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Impact factor
Select the library membership card:
DRS, in which the journal is indexed
| Database name | Field | Year |
|---|
| Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
|---|---|
| Chatzidionysiou, Katerina | ![]() |
| Lie, Elisabeth | ![]() |
| Nasonov, Evgen | ![]() |
| Tomšič, Matija, 1959- | 13601 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
| Pickup location | Material status | Reservation |
|---|
Please wait a moment.
